STRATA Skin Sciences Files Definitive Proxy Statement

TL;DR

STRATA Skin Sciences filed its proxy statement for the Oct 29 meeting. Vote your shares!

AI Summary

STRATA Skin Sciences, Inc. filed a definitive proxy statement (DEF 14A) on September 26, 2024, for its annual meeting on October 29, 2024. The filing concerns the solicitation of proxies from shareholders regarding matters to be voted on at the meeting. The company was formerly known as MELA SCIENCES, INC. and ELECTRO OPTICAL SCIENCES INC.

Why It Matters

This filing provides shareholders with crucial information about the upcoming annual meeting, including proposals to be voted on, and is essential for informed participation in corporate governance.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEF 14A) that provides information to shareholders about an upcoming meeting, rather than announcing significant new business developments.

Key Players & Entities

• STRATA Skin Sciences, Inc. (company) — Registrant
• MELA SCIENCES, INC. (company) — Former company name
• ELECTRO OPTICAL SCIENCES INC (company) — Former company name
• 20240926 (date) — Filing date
• 20241029 (date) — Meeting date

FAQ

Filing Documents

• ny20034324x1_def14a.htm (DEF 14A) — 619KB
• ny20034324x1_pvpchart01.jpg (GRAPHIC) — 146KB
• ny20034324x1_pvpchart02.jpg (GRAPHIC) — 149KB
• ny20034324x1_pc1.jpg (GRAPHIC) — 480KB
• ny20034324x1_pc2.jpg (GRAPHIC) — 477KB
• 0001140361-24-042050.txt ( ) — 2344KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT     5 CORPORATE GOVERNANCE     6 REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS     10 SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE     11

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION     12 DIRECTOR COMPENSATION     21 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS     22 PROPOSAL NO. 1     23 PROPOSAL NO. 2     25 HOUSEHOLDING OF PROXY MATERIALS     27 OTHER MATTERS     28         i TABLE OF CONTENTS STRATA SKIN SCIENCES, INC. 5 Walnut Grove Drive, Suite 140 Horsham, Pennsylvania 19044 PROXY STATEMENT FOR THE   2024 ANNUAL MEETING OF STOCKHOLDERS QUESTIONS AND ANSWERS ABOUT THIS PROXY MATERIAL AND VOTING Why am I receiving these materials? We sent you this Proxy Statement and the enclosed proxy card because the Board of Directors of STRATA Skin Sciences, Inc. (“we”, “us”, “our”, or “the Company”) is soliciting your proxy to vote at our 2024 Annual Meeting of Stockholders (the “Annual Meeting”). You are invited to attend the Annual Meeting, and we request that you vote on the proposals described in this Proxy Statement. You do not need to attend the meeting to vote your shares. Instead, you may simply complete, sign and return the enclosed proxy card, or you may grant a proxy to vote your shares by means of the telephone or on the Internet. We intend to mail this Proxy Statement and the accompanying proxy card together with our 2024 Annual Report to Stockholders on or about September 26, 2024 to all stockholders of record on September 19, 2024 (the “record date”) entitled to vote at the Annual Meeting. Each share of common stock outstanding on the record date will be entitled to one vote. Who can vote at the Annual Meeting? Only stockholders of record at the close of business on the record date will be entitled to vote at the Annual Meeting. On this record date, there were 4,171,161 shares of common stock outstanding and entitled to vote. Stockholder of Record: Shares Re

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT The following table reflects, as of March 31, 2024, the beneficial common stock ownership of: (a) each of our directors, (b) each executive officer, (c) each person known by us to be a beneficial holder of five percent (5%) or more of our common stock, and (d) all of our executive officers and directors as a group. Unless otherwise provided in the accompanying footnotes, the information used in the table below was obtained from the referenced beneficial owner. The information below reflects the outcome of the 1-for-10 reverse stock split undertaken by the Company on June 6, 2024.               Name and Address of Beneficial Owner (1)     Number of Shares Beneficially Owned     Percentage of Shares Beneficially Owned (1) Uri Geiger (5)     1,211,262     34.55% Dolev Rafaeli (8)     138,602     3.95% Robert J. Moccia (2)     0       Wayne Cafran (9)     0     * Irit Yaniv (9)     0     * Shmuel Rubinstein (10)     18,326     * Christopher Lesovitz (3)     213,282     * Shmuel Gov (4)     46,748     * All directors and officers as a group (seven persons)     1,628,220     39%               Accelmed Partners LP (5)     1,211,262     34.55% Nantahala Capital Management, LLC (6)     312,813     8.92% 22NW Fund, LP (7)     536,995     15.32%               * Less than 1%. (1) Beneficial ownership is determined in accordance with the rules

View Full Filing

View this DEF 14A filing on SEC EDGAR